Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A5 | P20815 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 5/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988520 | 0.91 | USP30 (0.36) | USP30NPC1DRD2DRD4 | |
| SCHEMBL986580 | 0.90 | DRD2 (0.37) | USP30NPC1DRD2DRD4 | |
| SCHEMBL988294 | 0.89 | DRD2 (0.37) | CNR2USP30NPC1DRD2DRD4 | |
| SCHEMBL988567 | 0.89 | PDPK1 (0.37) | CYP3A5CNR2USP30GLSMCHR1 | |
| SCHEMBL987768 | 0.88 | PTGER4 (0.41) | CYP3A5CNR2USP30GLSNPC1 | |
| SCHEMBL13619452 | 0.88 | DRD2 (0.37) | CYP3A5CNR2USP30GLSNPC1 | |
| SCHEMBL987756 | 0.88 | ACACB (0.35) | CYP3A5GLSMCHR1 | |
| Bicarbonate SCHEMBL16143669 | 0.88 | NPC1 (0.44) | CYP3A5CNR2USP30GLSNPC1 | |
| SCHEMBL988225 | 0.84 | DRD2 (0.42) | DRD2 | |
| SCHEMBL987690 | 0.84 | KDM4E (0.35) | CYP3A5CNR2NPC1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2565191-B1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | ASTELLAS PHARMA INC (JP) | 2014-10-08 | — | — | EP | claimed |
| US-8598355-B2 | Amide compound | ASTELLAS PHARMA INC. (JP) | 2013-12-03 | — | — | US | claimed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | claimed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | claimed |
| US-8598355-B2 | Amide compound | ASTELLAS PHARMA INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2565191-A1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | CYP3A5 2792/4885CNR2 11/4885USP30 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.